Tag: type 2 diabetes industry

Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.

Type 2 Diabetes Market Revenue Growth Supported By A CAGR Of 78.66% Through 2030

The market for type 2 diabetes treatments has experienced robust expansion. Projections indicate a rise from $51.47 billion in 2025 to $55.53 billion by 2026, reflecting a compound annual growth rate of 7.9%. Key factors contributing to the market’s historical surge include the escalating worldwide incidence of obesity, a rise in physically inactive lifestyles, broader accessibility to oral antidiabetic medications, enhanced detection of metabolic conditions, and improvements in accessing foundational diabetes care.

The market for type 2 diabetes treatments is poised for significant expansion, with projections indicating a substantial increase to $78.67 billion by the year 2030, reflecting a compound annual growth rate of 9.1%. This anticipated surge is fueled by several key factors, including a heightened demand for therapeutic options that prioritize weight management, a growing tendency towards individualized diabetes care strategies, the broadening reach of digital health solutions, an intensified focus on preventing the onset of diabetes, and increased investment in the development of innovative antidiabetic medications. Furthermore, prevailing trends expected to shape this market during the forecast period encompass a greater utilization of GLP-1 receptor agonists, an elevated emphasis on managing cardiometabolic risks concurrently, a rise in the application of combination therapies, the wider integration of lifestyle-based treatment modalities, and a stronger commitment to achieving sustained glycemic control over the long term.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13050&type=smp

Type 2 Diabetes Market Opportunity Drivers: What Is Creating New Revenue Potential?

The escalating prevalence of obesity and cardiovascular ailments is anticipated to be a significant catalyst for the expansion of the type 2 diabetes market. Obesity, characterized by an unhealthy accumulation of body fat, and heart disease, encompassing various conditions affecting the heart and its vasculature, are closely linked to the rise of type 2 diabetes. Excessive weight gain heightens the likelihood of insulin resistance, resulting in elevated blood glucose levels and the subsequent onset of type 2 diabetes. Conversely, persistently high blood sugar can inflict damage upon the blood vessels and the neural pathways governing cardiovascular function, thereby contributing to heart disease. As an illustration, a report issued in March 2024 by the World Health Organization (WHO), an international body headquartered in Switzerland, indicated that nearly 12.5% of the global population faces the challenge of obesity, with 2.5 billion adults (18 and above) being overweight, and 890 million of these individuals classified as obese. Within the adult demographic, 43% were identified as overweight, and 16% met the criteria for obesity. Furthermore, the figure for overweight children under five years of age stood at 37 million. Consequently, the increasing incidence of obesity and heart disease is a direct driver behind the growth observed in the type 2 diabetes market.

Type 2 Diabetes Market Segments: Where Are The Largest Growth Opportunities?

The type 2 diabetes market covered in this report is segmented –

1) By Drug Class: Dipeptidyl Peptidase-4 (DPP-4) Inhibitors, Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists, Thiazolidinediones, Alpha-Glucosidase Inhibitors, Sulfonylureas And Insulin Secretagogues, Biguanides, SodiumGlucose Cotransporter 2 Inhibitors, Other Drug Classes

2) By Application: Glycemic Control, Cardiovascular Safety, Hypoglycemia Avoidance, Other Applications

3) By End-User: Children, Adults

Subsegments:

1) By Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: Sitagliptin, Saxagliptin, Linagliptin, Alogliptin

2) By Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists: Liraglutide, Semaglutide, Dulaglutide, Exenatide

3) By Thiazolidinediones: Pioglitazone, Rosiglitazone

4) By Alpha-Glucosidase Inhibitors: Acarbose, Miglitol

5) By Sulfonylureas And Insulin Secretagogues: Glimepiride, Glipizide, Glyburide

6) By Biguanides: Metformin, Buformin, Phenformin

7) By Sodium-Glucose Cotransporter 2 Inhibitors: Canagliflozin, Dapagliflozin, Empagliflozin

8) By Other Drug Classes: Amylin Analogues, Bile Acid Sequestrants, Dopamine Agonists

Type 2 Diabetes Market Innovation Trends Driving Future Development

Leading pharmaceutical firms in the type 2 diabetes sector are prioritizing the creation of innovative treatments, specifically dual-action SGLT2/GLP-1 therapies with expanded uses, aiming to achieve superior blood sugar management, mitigate associated health complications, and boost patient compliance. These combined SGLT2 inhibitor and GLP-1 receptor agonist therapies, also available as fixed-dose preparations, are designed to concurrently address glucose regulation, weight management, and cardiovascular and kidney health in individuals diagnosed with type 2 diabetes. A notable development occurred in June 2024 when AstraZeneca, a biopharmaceutical giant, secured U.S. FDA authorization for Farxiga (dapagliflozin) to treat type 2 diabetes in pediatric patients aged 10 and above, signifying a strategic move to encompass a wider demographic beyond adults. This advancement provides a convenient once-daily oral option for younger individuals, incorporates comprehensive data on cardioprotective and renoprotective benefits, and facilitates market penetration into pediatric and nascent stages of type 2 diabetes, thereby propelling the expansion of the worldwide type 2 diabetes market.

Type 2 Diabetes Market Major Participants And Competitive Dynamics

Major companies operating in the type 2 diabetes market are F. Hoffmann-La Roche AG, Merck and Co. Inc, Novartis AG, AstraZeneca plc, Abbott Laboratories, Sanofi SA, Medtronic plc, Takeda Pharmaceutical Company, GlaxoSmithKline plc, Eli Lilly and Company, Novo Nordisk A/S, Johnson And Johnson Private Limited, Daiichi Sankyo Co. Ltd, Boehringer Ingelheim International GmbH, Dexcom Inc, Amgen Inc., Insulet Corporation, Ascensia Diabetes Care, Beta Bionics, Onduo LLC, DarioHealth, One Drop, Bigfoot Biomedical Inc., Digbi Health, MySugr GmbH, Senseonics Holdings Inc., Provention Bio Inc., Vida Health Inc., Diathrive Health

Access The Complete Type 2 Diabetes Market Report:

https://www.thebusinessresearchcompany.com/report/type-2-diabetes-global-market-report

Type 2 Diabetes Market Global Footprint: Which Region Holds Market Leadership?

North Americawas the largest region in the type 2 diabetes market in 2025. Europeis expected to be the fastest-growing region in the forecast period. The regions covered in the type 2 diabetes market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Is The Estimated Growth In Market Size Of The Type 2 Diabetes Market During 2026–2030?

The type 2 diabetes market has shown significant expansion in recent years. It is anticipated to increase from $51.47 billion in 2025 to $55.53 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 7.9%. Historically, this market’s growth can be linked to factors like the escalating global obesity rates, the rise in sedentary behaviors, broader access to oral antidiabetic drugs, increased screening for metabolic disorders, and improved provision of primary diabetes care.

The type 2 diabetes market is projected to experience substantial expansion in the coming years, anticipated to reach $78.67 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 9.1%. This growth during the forecast period is primarily driven by factors such as a heightened demand for therapies centered on weight management, a surge in the adoption of individualized diabetes treatment strategies, the broadening of digital therapeutic platforms, an intensified focus on proactive diabetes prevention, and increased capital flow into innovative antidiabetic medications. Key trends emerging in this period encompass the growing uptake of GLP-1 receptor agonists, an increased emphasis on managing cardiometabolic risks, the expanding utilization of multi-drug therapies, the development of treatment methods that integrate lifestyle changes, and a stronger commitment to achieving sustained glycemic control.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13050&type=smp

Which Strategic Drivers Are Supporting The Type 2 Diabetes Market Development?

The forward trajectory of the type 2 diabetes market is anticipated to be driven by escalating incidences of obesity and heart disease. Obesity is defined as a medical state where an unhealthy accumulation of excess body fat occurs, whereas heart disease encompasses various ailments impacting the heart and its associated blood vessels. Elevated body weight raises the likelihood of insulin resistance, which in turn results in elevated blood sugar and the onset of type 2 diabetes. Conversely, high blood glucose concentrations can harm the blood vessels and nerves vital for cardiac and circulatory function, culminating in heart disease. As an illustration, in March 2024, the World Health Organization (WHO), an intergovernmental entity situated in Switzerland, disclosed that roughly one in eight individuals globally contended with obesity. This figure comprised 2.5 billion adults (18 years and older) who were categorized as overweight, with 890 million of these individuals experiencing obesity. Among the adult demographic, 43% were overweight, and 16% were identified as obese. Furthermore, the population of overweight children under the age of 5 reached 37 million. Consequently, the escalating prevalence of obesity and heart disease is fueling the expansion of the type 2 diabetes market.

How Is The Type 2 Diabetes Market Structured Across Different Market Segments?

The type 2 diabetes market covered in this report is segmented –

1) By Drug Class: Dipeptidyl Peptidase-4 (DPP-4) Inhibitors, Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists, Thiazolidinediones, Alpha-Glucosidase Inhibitors, Sulfonylureas And Insulin Secretagogues, Biguanides, SodiumGlucose Cotransporter 2 Inhibitors, Other Drug Classes

2) By Application: Glycemic Control, Cardiovascular Safety, Hypoglycemia Avoidance, Other Applications

3) By End-User: Children, Adults

Subsegments:

1) By Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: Sitagliptin, Saxagliptin, Linagliptin, Alogliptin

2) By Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists: Liraglutide, Semaglutide, Dulaglutide, Exenatide

3) By Thiazolidinediones: Pioglitazone, Rosiglitazone

4) By Alpha-Glucosidase Inhibitors: Acarbose, Miglitol

5) By Sulfonylureas And Insulin Secretagogues: Glimepiride, Glipizide, Glyburide

6) By Biguanides: Metformin, Buformin, Phenformin

7) By Sodium-Glucose Cotransporter 2 Inhibitors: Canagliflozin, Dapagliflozin, Empagliflozin

8) By Other Drug Classes: Amylin Analogues, Bile Acid Sequestrants, Dopamine Agonists

Which Trends Are Expected To Shape The Type 2 Diabetes Market?

Leading companies within the type 1 diabetes market are prioritizing the creation of advanced therapeutic solutions, such as allogeneic islet cell transplantation, aiming to provide functional beta-cell replacement and diminish insulin reliance for type 1 diabetes patients. Allogeneic islet cell transplantation is defined as the introduction of donor pancreatic islet cells into a patient’s hepatic portal vein, with the goal of re-establishing internal insulin production and decreasing the occurrence of hypoglycemic incidents and insulin injections. For example, in June 2023, CellTrans Inc., a US-based biotechnology firm, obtained clearance from the U.S. Food and Drug Administration (FDA) for Lantidra (donislecel), marking it as the first cellular therapy specifically for type 1 diabetes patients. This approval signifies a major breakthrough in regenerative medicine, presenting a possible enduring treatment alternative for individuals with type 1 diabetes who contend with insulin dependence. Lantidra operates by substituting the insulin-producing cells eradicated by the immune system, thereby striving to reinstate the body’s inherent capacity to manage blood glucose levels.

Which Companies Are Engaged In The Type 2 Diabetes Market Environment?

Major companies operating in the type 2 diabetes market are F. Hoffmann-La Roche AG, Merck and Co. Inc, Novartis AG, AstraZeneca plc, Abbott Laboratories, Sanofi SA, Medtronic plc, Takeda Pharmaceutical Company, GlaxoSmithKline plc, Eli Lilly and Company, Novo Nordisk A/S, Johnson And Johnson Private Limited, Daiichi Sankyo Co. Ltd, Boehringer Ingelheim International GmbH, Dexcom Inc, Amgen Inc., Insulet Corporation, Ascensia Diabetes Care, Beta Bionics, Onduo LLC, DarioHealth, One Drop, Bigfoot Biomedical Inc., Digbi Health, MySugr GmbH, Senseonics Holdings Inc., Provention Bio Inc., Vida Health Inc., Diathrive Health

Access The Complete Type 2 Diabetes Market Report:

https://www.thebusinessresearchcompany.com/report/type-2-diabetes-global-market-report

What Is The Largest Regional Market In The Type 2 Diabetes Market?

North America was the largest region in the type 2 diabetes market in 2025. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the type 2 diabetes market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Type 2 Diabetes Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/customise?id=13050&type=smp

Browse Through More Reports Similar to the Global Type 2 Diabetes Market 2026, By The Business Research Company

Type 1 Diabetes Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/type-1-diabetes-global-market-report

Antidiabetics Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/antidiabetics-global-market-report

Diabetes Care Devices Market 2026

https://www.thebusinessresearchcompany.com/report/diabetes-care-devices-market

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

By 2030, What Market Size Is The Type 2 Diabetes Market Expected To Reach Based On Its 2026 Value?

The type 2 diabetes market size has seen robust growth in recent years. It is projected to expand from $51.47 billion in 2025 to $55.53 billion in 2026, at a compound annual growth rate (CAGR) of 7.9%. The market’s historical growth can be attributed to the escalating global prevalence of obesity, increased sedentary lifestyles, the expansion of oral antidiabetic drug availability, growing screening for metabolic disorders, and improved access to primary diabetes care.

The type 2 diabetes market is anticipated to show significant expansion over the next few years. It will grow to $78.67 billion in 2030 at a compound annual growth rate (CAGR) of 9.1%. This growth during the forecast period is driven by factors such as an increasing demand for therapies focused on weight management, a rising embrace of personalized diabetes treatment approaches, the expansion of digital therapeutic platforms, a growing emphasis on preventive diabetes management, and increased investments in next-generation antidiabetic drugs. Notable trends expected in this period include the increasing adoption of GLP-1 receptor agonists, a heightened focus on cardiometabolic risk management, the growing application of combination drug therapies, the expansion of lifestyle-integrated treatment strategies, and an enhanced emphasis on achieving long-term glycemic control.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13050&type=smp

Which Drivers Are Supporting The Type 2 Diabetes Market Growth?

The escalating incidence of obesity and heart disease is projected to fuel the growth of the type 2 diabetes market moving forward. Obesity is defined as a medical state where excessive body fat has accumulated to an unhealthy degree, while heart disease refers to various conditions that impact the heart and its blood vessels. Elevated body weight increases the probability of insulin resistance, leading to high blood sugar levels and the subsequent development of type 2 diabetes. Conversely, high blood sugar levels can damage the blood vessels and nerves that regulate the heart and its vessels, contributing to heart disease. For example, in March 2024, the World Health Organization (WHO), a Switzerland-based intergovernmental entity, reported that approximately one in eight people globally were struggling with obesity. This included 2.5 billion adults (aged 18 years and older) who were overweight, with 890 million of them living with obesity. Among adults, 43% were overweight, and 16% were classified as obese. Additionally, the number of overweight children under the age of 5 reached 37 million. Therefore, the rising rates of obesity and heart disease are driving the expansion of the type 2 diabetes market.

Which Segment Classifications Are Used In The Type 2 Diabetes Market Segment Analysis?

The type 2 diabetes market covered in this report is segmented –

1) By Drug Class: Dipeptidyl Peptidase-4 (DPP-4) Inhibitors, Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists, Thiazolidinediones, Alpha-Glucosidase Inhibitors, Sulfonylureas And Insulin Secretagogues, Biguanides, SodiumGlucose Cotransporter 2 Inhibitors, Other Drug Classes

2) By Application: Glycemic Control, Cardiovascular Safety, Hypoglycemia Avoidance, Other Applications

3) By End-User: Children, Adults

Subsegments:

1) By Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: Sitagliptin, Saxagliptin, Linagliptin, Alogliptin

2) By Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists: Liraglutide, Semaglutide, Dulaglutide, Exenatide

3) By Thiazolidinediones: Pioglitazone, Rosiglitazone

4) By Alpha-Glucosidase Inhibitors: Acarbose, Miglitol

5) By Sulfonylureas And Insulin Secretagogues: Glimepiride, Glipizide, Glyburide

6) By Biguanides: Metformin, Buformin, Phenformin

7) By Sodium-Glucose Cotransporter 2 Inhibitors: Canagliflozin, Dapagliflozin, Empagliflozin

8) By Other Drug Classes: Amylin Analogues, Bile Acid Sequestrants, Dopamine Agonists

Which Trends Are Expected To Impact The Type 2 Diabetes Market?

Leading companies in the type 2 diabetes market are concentrating on developing advanced solutions, such as extended-indication SGLT2/GLP-1 combination therapies, to achieve improved glycemic control, mitigate comorbidities, and enhance patient adherence. These extended-indication SGLT2/GLP-1 combination therapies are pharmaceutical regimens combining sodium-glucose co-transporter-2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists (or their fixed-dose combinations) to concurrently address blood glucose regulation, obesity, and cardiovascular and renal outcomes in type 2 diabetes patients. For instance, in June 2024, AstraZeneca, a UK-based pharmaceutical company, obtained U.S. FDA approval for Farxiga (dapagliflozin) for the paediatric type 2 diabetes indication (age 10 years and older), extending its usage beyond adult populations and signifying a strategy for a broader patient base. This particular innovation provides once-daily oral dosing for younger patients, incorporates cardiometabolic and renal protection data, and enables market expansion into paediatric and early-stage type 2 diabetes segments, consequently stimulating growth in the global type 2 diabetes market.

Which Firms Are Contributing To The Type 2 Diabetes Market Ecosystem?

Major companies operating in the type 2 diabetes market are F. Hoffmann-La Roche AG, Merck and Co. Inc, Novartis AG, AstraZeneca plc, Abbott Laboratories, Sanofi SA, Medtronic plc, Takeda Pharmaceutical Company, GlaxoSmithKline plc, Eli Lilly and Company, Novo Nordisk A/S, Johnson And Johnson Private Limited, Daiichi Sankyo Co. Ltd, Boehringer Ingelheim International GmbH, Dexcom Inc, Amgen Inc., Insulet Corporation, Ascensia Diabetes Care, Beta Bionics, Onduo LLC, DarioHealth, One Drop, Bigfoot Biomedical Inc., Digbi Health, MySugr GmbH, Senseonics Holdings Inc., Provention Bio Inc., Vida Health Inc., Diathrive Health

Get The Full Type 2 Diabetes Market Report:

https://www.thebusinessresearchcompany.com/report/type-2-diabetes-global-market-report

Where Is The Type 2 Diabetes Market Most Concentrated Geographically?

North America was the largest region in the type 2 diabetes market in 2025. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the type 2 diabetes market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Type 2 Diabetes Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/type-2-diabetes-global-market-report

Browse Through More Reports Similar to the Global Type 2 Diabetes Market 2026, By The Business Research Company

Type 1 Diabetes Market Report 2026

https://www.thebusinessresearchcompany.com/report/type-1-diabetes-global-market-report

Antidiabetics Market Report

https://www.thebusinessresearchcompany.com/report/antidiabetics-global-market-report

Diabetes Care Devices Market

https://www.thebusinessresearchcompany.com/report/diabetes-care-devices-market

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Is The Expected Market Size Of The Type 2 Diabetes Market From 2026 To 2030?

The type 2 diabetes market has experienced robust expansion in recent years. It is projected to expand from $51.47 billion in 2025 to $55.53 billion in 2026, achieving a compound annual growth rate (CAGR) of 7.9%. The market’s historical growth can be attributed to the rising global prevalence of obesity, increasingly sedentary lifestyles, the broader availability of oral antidiabetic drugs, growing screening efforts for metabolic disorders, and improved access to primary diabetes care.

The type 2 diabetes market size is anticipated to undergo significant expansion in the upcoming years. It is projected to reach $78.67 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 9.1%. This expansion over the forecast period can be attributed to several factors, including an increased demand for weight-management focused therapies, a growing adoption of personalized diabetes treatment plans, the spread of digital therapeutic platforms, a heightened focus on preventive diabetes management, and increased investments in next-generation antidiabetic drugs. Notable trends during this period are expected to include the rising adoption of GLP-1 receptor agonists, an increased emphasis on cardiometabolic risk management, the broader use of combination drug therapies, the development of lifestyle-integrated treatment approaches, and a stronger focus on long-term glycemic control.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13050&type=smp

What Drivers Are Influencing The Type 2 Diabetes Market?

The increasing prevalence of obesity and heart disease is anticipated to propel the expansion of the type 2 diabetes market in the future. Obesity is a medical condition defined by an unhealthy accumulation of excess body fat, whereas heart disease encompasses various conditions affecting the heart and blood vessels. Elevated body weight raises the risk of insulin resistance, leading to high blood sugar levels and the subsequent development of type 2 diabetes. Conversely, high blood sugar levels can damage blood vessels and nerves that control the heart and blood vessels, potentially resulting in heart disease. For example, in March 2024, the World Health Organization (WHO), a Switzerland-based intergovernmental organization, reported that approximately one in eight people globally were grappling with obesity. This included 2.5 billion adults (aged 18 years and older) who were overweight, with 890 million of them living with obesity. Among adults, 43% were considered overweight, and 16% were categorized as obese. Furthermore, the number of overweight children under the age of 5 reached 37 million. Thus, the rising rates of obesity and heart disease are driving the growth of the type 2 diabetes market.

Which Segments Are Included In The Analysis Of The Type 2 Diabetes Market?

The type 2 diabetes market covered in this report is segmented –

1) By Drug Class: Dipeptidyl Peptidase-4 (DPP-4) Inhibitors, Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists, Thiazolidinediones, Alpha-Glucosidase Inhibitors, Sulfonylureas And Insulin Secretagogues, Biguanides, SodiumGlucose Cotransporter 2 Inhibitors, Other Drug Classes

2) By Application: Glycemic Control, Cardiovascular Safety, Hypoglycemia Avoidance, Other Applications

3) By End-User: Children, Adults

Subsegments:

1) By Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: Sitagliptin, Saxagliptin, Linagliptin, Alogliptin

2) By Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists: Liraglutide, Semaglutide, Dulaglutide, Exenatide

3) By Thiazolidinediones: Pioglitazone, Rosiglitazone

4) By Alpha-Glucosidase Inhibitors: Acarbose, Miglitol

5) By Sulfonylureas And Insulin Secretagogues: Glimepiride, Glipizide, Glyburide

6) By Biguanides: Metformin, Buformin, Phenformin

7) By Sodium-Glucose Cotransporter 2 Inhibitors: Canagliflozin, Dapagliflozin, Empagliflozin

8) By Other Drug Classes: Amylin Analogues, Bile Acid Sequestrants, Dopamine Agonists

What Trends Are Affecting The Expansion Of The Type 2 Diabetes Market?

Major companies operating in the type 2 diabetes market are concentrating on creating advanced solutions, such as expanded-indication SGLT2/GLP-1 combination therapies, to achieve improved glycemic control, mitigate comorbidities, and boost patient adherence. These expanded-indication SGLT2/GLP-1 combination therapies represent drug regimens that integrate sodium-glucose co-transporter-2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists (or their fixed-dose combinations) to address blood glucose management, obesity, and cardiovascular and renal health in individuals with type 2 diabetes concurrently. For example, in June 2024, the UK-based pharmaceutical firm AstraZeneca secured U.S. FDA approval for Farxiga (dapagliflozin) for the paediatric type 2 diabetes indication (age 10 years and older), thereby extending its application beyond adult populations and indicating a wider patient outreach approach. This particular advancement provides once-daily oral administration for younger patients, includes data on cardiometabolic and renal protection, and facilitates market entry into paediatric and early-stage type 2 diabetes sectors, thereby fueling expansion in the global type 2 diabetes market.

Which Key Industry Participants Are Active In The Type 2 Diabetes Market?

Major companies operating in the type 2 diabetes market are F. Hoffmann-La Roche AG, Merck and Co. Inc, Novartis AG, AstraZeneca plc, Abbott Laboratories, Sanofi SA, Medtronic plc, Takeda Pharmaceutical Company, GlaxoSmithKline plc, Eli Lilly and Company, Novo Nordisk A/S, Johnson And Johnson Private Limited, Daiichi Sankyo Co. Ltd, Boehringer Ingelheim International GmbH, Dexcom Inc, Amgen Inc., Insulet Corporation, Ascensia Diabetes Care, Beta Bionics, Onduo LLC, DarioHealth, One Drop, Bigfoot Biomedical Inc., Digbi Health, MySugr GmbH, Senseonics Holdings Inc., Provention Bio Inc., Vida Health Inc., Diathrive Health

Read the full type 2 diabetes market report here:

https://www.thebusinessresearchcompany.com/report/type-2-diabetes-global-market-report

Which Regions Are Expected To Experience Rapid Expansion In The Type 2 Diabetes Market?

North America was the largest region in the type 2 diabetes market in 2025. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the type 2 diabetes market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Type 2 Diabetes Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=13050&type=smp

Browse Through More Reports Similar to the Global Type 2 Diabetes Market 2026, By The Business Research Company

Type 1 Diabetes Global Market Report

https://www.thebusinessresearchcompany.com/report/type-1-diabetes-global-market-report

Antidiabetics Global Market Report

https://www.thebusinessresearchcompany.com/report/antidiabetics-global-market-report

Diabetes Care Devices Market

https://www.thebusinessresearchcompany.com/report/diabetes-care-devices-market

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Is The Expected Market Size Of The Type 2 Diabetes Market From 2026 To 2030?

The type 2 diabetes market has experienced robust expansion in recent years. It is projected to expand from $51.47 billion in 2025 to $55.53 billion in 2026, achieving a compound annual growth rate (CAGR) of 7.9%. The market’s historical growth can be attributed to the rising global prevalence of obesity, increasingly sedentary lifestyles, the broader availability of oral antidiabetic drugs, growing screening efforts for metabolic disorders, and improved access to primary diabetes care.

The type 2 diabetes market size is anticipated to undergo significant expansion in the upcoming years. It is projected to reach $78.67 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 9.1%. This expansion over the forecast period can be attributed to several factors, including an increased demand for weight-management focused therapies, a growing adoption of personalized diabetes treatment plans, the spread of digital therapeutic platforms, a heightened focus on preventive diabetes management, and increased investments in next-generation antidiabetic drugs. Notable trends during this period are expected to include the rising adoption of GLP-1 receptor agonists, an increased emphasis on cardiometabolic risk management, the broader use of combination drug therapies, the development of lifestyle-integrated treatment approaches, and a stronger focus on long-term glycemic control.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13050&type=smp

What Drivers Are Influencing The Type 2 Diabetes Market?

The increasing prevalence of obesity and heart disease is anticipated to propel the expansion of the type 2 diabetes market in the future. Obesity is a medical condition defined by an unhealthy accumulation of excess body fat, whereas heart disease encompasses various conditions affecting the heart and blood vessels. Elevated body weight raises the risk of insulin resistance, leading to high blood sugar levels and the subsequent development of type 2 diabetes. Conversely, high blood sugar levels can damage blood vessels and nerves that control the heart and blood vessels, potentially resulting in heart disease. For example, in March 2024, the World Health Organization (WHO), a Switzerland-based intergovernmental organization, reported that approximately one in eight people globally were grappling with obesity. This included 2.5 billion adults (aged 18 years and older) who were overweight, with 890 million of them living with obesity. Among adults, 43% were considered overweight, and 16% were categorized as obese. Furthermore, the number of overweight children under the age of 5 reached 37 million. Thus, the rising rates of obesity and heart disease are driving the growth of the type 2 diabetes market.

Which Segments Are Included In The Analysis Of The Type 2 Diabetes Market?

The type 2 diabetes market covered in this report is segmented –

1) By Drug Class: Dipeptidyl Peptidase-4 (DPP-4) Inhibitors, Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists, Thiazolidinediones, Alpha-Glucosidase Inhibitors, Sulfonylureas And Insulin Secretagogues, Biguanides, SodiumGlucose Cotransporter 2 Inhibitors, Other Drug Classes

2) By Application: Glycemic Control, Cardiovascular Safety, Hypoglycemia Avoidance, Other Applications

3) By End-User: Children, Adults

Subsegments:

1) By Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: Sitagliptin, Saxagliptin, Linagliptin, Alogliptin

2) By Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists: Liraglutide, Semaglutide, Dulaglutide, Exenatide

3) By Thiazolidinediones: Pioglitazone, Rosiglitazone

4) By Alpha-Glucosidase Inhibitors: Acarbose, Miglitol

5) By Sulfonylureas And Insulin Secretagogues: Glimepiride, Glipizide, Glyburide

6) By Biguanides: Metformin, Buformin, Phenformin

7) By Sodium-Glucose Cotransporter 2 Inhibitors: Canagliflozin, Dapagliflozin, Empagliflozin

8) By Other Drug Classes: Amylin Analogues, Bile Acid Sequestrants, Dopamine Agonists

What Trends Are Affecting The Expansion Of The Type 2 Diabetes Market?

Major companies operating in the type 2 diabetes market are concentrating on creating advanced solutions, such as expanded-indication SGLT2/GLP-1 combination therapies, to achieve improved glycemic control, mitigate comorbidities, and boost patient adherence. These expanded-indication SGLT2/GLP-1 combination therapies represent drug regimens that integrate sodium-glucose co-transporter-2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists (or their fixed-dose combinations) to address blood glucose management, obesity, and cardiovascular and renal health in individuals with type 2 diabetes concurrently. For example, in June 2024, the UK-based pharmaceutical firm AstraZeneca secured U.S. FDA approval for Farxiga (dapagliflozin) for the paediatric type 2 diabetes indication (age 10 years and older), thereby extending its application beyond adult populations and indicating a wider patient outreach approach. This particular advancement provides once-daily oral administration for younger patients, includes data on cardiometabolic and renal protection, and facilitates market entry into paediatric and early-stage type 2 diabetes sectors, thereby fueling expansion in the global type 2 diabetes market.

Which Key Industry Participants Are Active In The Type 2 Diabetes Market?

Major companies operating in the type 2 diabetes market are F. Hoffmann-La Roche AG, Merck and Co. Inc, Novartis AG, AstraZeneca plc, Abbott Laboratories, Sanofi SA, Medtronic plc, Takeda Pharmaceutical Company, GlaxoSmithKline plc, Eli Lilly and Company, Novo Nordisk A/S, Johnson And Johnson Private Limited, Daiichi Sankyo Co. Ltd, Boehringer Ingelheim International GmbH, Dexcom Inc, Amgen Inc., Insulet Corporation, Ascensia Diabetes Care, Beta Bionics, Onduo LLC, DarioHealth, One Drop, Bigfoot Biomedical Inc., Digbi Health, MySugr GmbH, Senseonics Holdings Inc., Provention Bio Inc., Vida Health Inc., Diathrive Health

Read the full type 2 diabetes market report here:

https://www.thebusinessresearchcompany.com/report/type-2-diabetes-global-market-report

Which Regions Are Expected To Experience Rapid Expansion In The Type 2 Diabetes Market?

North America was the largest region in the type 2 diabetes market in 2025. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the type 2 diabetes market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Type 2 Diabetes Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=13050&type=smp

Browse Through More Reports Similar to the Global Type 2 Diabetes Market 2026, By The Business Research Company

Type 1 Diabetes Global Market Report

https://www.thebusinessresearchcompany.com/report/type-1-diabetes-global-market-report

Antidiabetics Global Market Report

https://www.thebusinessresearchcompany.com/report/antidiabetics-global-market-report

Diabetes Care Devices Market

https://www.thebusinessresearchcompany.com/report/diabetes-care-devices-market

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Is The Expected Market Size Of The Type 2 Diabetes Market From 2026 To 2030?

The type 2 diabetes market has experienced robust expansion in recent years. It is projected to expand from $51.47 billion in 2025 to $55.53 billion in 2026, achieving a compound annual growth rate (CAGR) of 7.9%. The market’s historical growth can be attributed to the rising global prevalence of obesity, increasingly sedentary lifestyles, the broader availability of oral antidiabetic drugs, growing screening efforts for metabolic disorders, and improved access to primary diabetes care.

The type 2 diabetes market size is anticipated to undergo significant expansion in the upcoming years. It is projected to reach $78.67 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 9.1%. This expansion over the forecast period can be attributed to several factors, including an increased demand for weight-management focused therapies, a growing adoption of personalized diabetes treatment plans, the spread of digital therapeutic platforms, a heightened focus on preventive diabetes management, and increased investments in next-generation antidiabetic drugs. Notable trends during this period are expected to include the rising adoption of GLP-1 receptor agonists, an increased emphasis on cardiometabolic risk management, the broader use of combination drug therapies, the development of lifestyle-integrated treatment approaches, and a stronger focus on long-term glycemic control.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13050&type=smp

What Drivers Are Influencing The Type 2 Diabetes Market?

The increasing prevalence of obesity and heart disease is anticipated to propel the expansion of the type 2 diabetes market in the future. Obesity is a medical condition defined by an unhealthy accumulation of excess body fat, whereas heart disease encompasses various conditions affecting the heart and blood vessels. Elevated body weight raises the risk of insulin resistance, leading to high blood sugar levels and the subsequent development of type 2 diabetes. Conversely, high blood sugar levels can damage blood vessels and nerves that control the heart and blood vessels, potentially resulting in heart disease. For example, in March 2024, the World Health Organization (WHO), a Switzerland-based intergovernmental organization, reported that approximately one in eight people globally were grappling with obesity. This included 2.5 billion adults (aged 18 years and older) who were overweight, with 890 million of them living with obesity. Among adults, 43% were considered overweight, and 16% were categorized as obese. Furthermore, the number of overweight children under the age of 5 reached 37 million. Thus, the rising rates of obesity and heart disease are driving the growth of the type 2 diabetes market.

Which Segments Are Included In The Analysis Of The Type 2 Diabetes Market?

The type 2 diabetes market covered in this report is segmented –

1) By Drug Class: Dipeptidyl Peptidase-4 (DPP-4) Inhibitors, Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists, Thiazolidinediones, Alpha-Glucosidase Inhibitors, Sulfonylureas And Insulin Secretagogues, Biguanides, SodiumGlucose Cotransporter 2 Inhibitors, Other Drug Classes

2) By Application: Glycemic Control, Cardiovascular Safety, Hypoglycemia Avoidance, Other Applications

3) By End-User: Children, Adults

Subsegments:

1) By Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: Sitagliptin, Saxagliptin, Linagliptin, Alogliptin

2) By Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists: Liraglutide, Semaglutide, Dulaglutide, Exenatide

3) By Thiazolidinediones: Pioglitazone, Rosiglitazone

4) By Alpha-Glucosidase Inhibitors: Acarbose, Miglitol

5) By Sulfonylureas And Insulin Secretagogues: Glimepiride, Glipizide, Glyburide

6) By Biguanides: Metformin, Buformin, Phenformin

7) By Sodium-Glucose Cotransporter 2 Inhibitors: Canagliflozin, Dapagliflozin, Empagliflozin

8) By Other Drug Classes: Amylin Analogues, Bile Acid Sequestrants, Dopamine Agonists

What Trends Are Affecting The Expansion Of The Type 2 Diabetes Market?

Major companies operating in the type 2 diabetes market are concentrating on creating advanced solutions, such as expanded-indication SGLT2/GLP-1 combination therapies, to achieve improved glycemic control, mitigate comorbidities, and boost patient adherence. These expanded-indication SGLT2/GLP-1 combination therapies represent drug regimens that integrate sodium-glucose co-transporter-2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists (or their fixed-dose combinations) to address blood glucose management, obesity, and cardiovascular and renal health in individuals with type 2 diabetes concurrently. For example, in June 2024, the UK-based pharmaceutical firm AstraZeneca secured U.S. FDA approval for Farxiga (dapagliflozin) for the paediatric type 2 diabetes indication (age 10 years and older), thereby extending its application beyond adult populations and indicating a wider patient outreach approach. This particular advancement provides once-daily oral administration for younger patients, includes data on cardiometabolic and renal protection, and facilitates market entry into paediatric and early-stage type 2 diabetes sectors, thereby fueling expansion in the global type 2 diabetes market.

Which Key Industry Participants Are Active In The Type 2 Diabetes Market?

Major companies operating in the type 2 diabetes market are F. Hoffmann-La Roche AG, Merck and Co. Inc, Novartis AG, AstraZeneca plc, Abbott Laboratories, Sanofi SA, Medtronic plc, Takeda Pharmaceutical Company, GlaxoSmithKline plc, Eli Lilly and Company, Novo Nordisk A/S, Johnson And Johnson Private Limited, Daiichi Sankyo Co. Ltd, Boehringer Ingelheim International GmbH, Dexcom Inc, Amgen Inc., Insulet Corporation, Ascensia Diabetes Care, Beta Bionics, Onduo LLC, DarioHealth, One Drop, Bigfoot Biomedical Inc., Digbi Health, MySugr GmbH, Senseonics Holdings Inc., Provention Bio Inc., Vida Health Inc., Diathrive Health

Read the full type 2 diabetes market report here:

https://www.thebusinessresearchcompany.com/report/type-2-diabetes-global-market-report

Which Regions Are Expected To Experience Rapid Expansion In The Type 2 Diabetes Market?

North America was the largest region in the type 2 diabetes market in 2025. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the type 2 diabetes market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Type 2 Diabetes Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=13050&type=smp

Browse Through More Reports Similar to the Global Type 2 Diabetes Market 2026, By The Business Research Company

Type 1 Diabetes Global Market Report

https://www.thebusinessresearchcompany.com/report/type-1-diabetes-global-market-report

Antidiabetics Global Market Report

https://www.thebusinessresearchcompany.com/report/antidiabetics-global-market-report

Diabetes Care Devices Market

https://www.thebusinessresearchcompany.com/report/diabetes-care-devices-market

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model